APTARGROUP, INC. (ATR) Form 10-Q — Oct 30, 2026
AptarGroup reported Q3 2026 net sales of $1.02 billion, up 6% year over year, with core sales up 5% on strength in Beauty and Closures and growth in Pharma consumer healthcare and injectables. Reported net income fell to $32.6 million from $127.9 million, with diluted EPS of $0.51 versus $1.92, driven primarily by a one-time $58.0 million loss on the deconsolidation of its Russian subsidiary effective September 21, 2026. On an adjusted basis, diluted EPS was $1.52 versus $1.62 a year ago, and adjusted EBITDA margin compressed to 21.3% from 23.2%, reflecting higher input cost pass-through and Pharma emergency medicine declines.
Key figures
- Eps
- 0.51
- Revenue
- 1019119000
- Net Income
- 32602000
- Total Debt
- 1375416000
- Revenue Yoy
- 6%
- Total Assets
- 5111626000
- Cash Position
- 204176000
- Shares Outstanding
- 63388980
- Adjusted ebitda q3
- 217212000
- Nine month revenue
- 3028495000
- Core sales growth q3
- 5%
- Nine month net income
- 192849000
- Q3 dividend per share
- 0.48
- Nine month diluted eps
- 3
- Q3 adjusted diluted eps
- 1.52
- Adjusted ebitda margin q3
- 21.3%
- Q3 diluted eps prior year
- 1.92
- Free cash flow nine months
- 197813000
- Russia deconsolidation loss
- 58020000
- Buyback remaining authorization
- 420000000
- Q3 adjusted diluted eps prior year
- 1.62
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.